Grace Therapeutics, Inc. cotiza a 2.00 USD y tiene una capitalización bursátil de $42M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spr…
| Periodo | 2026-06 | 2026-02 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.08 | $-0.19 | $-0.08 | $-0.29 |
| Estimado | $-0.20 | $-0.39 | $-0.34 | $-0.31 |
| Sorpresa | +60.0% | +51.3% | +76.5% | +6.5% |
| Métrica | GRCE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -12.2% | -40.4% | +28.2% |
| ROA | -11.7% | -32.0% | +20.3% |
| Current Ratio | 8.10 | 2.84 | +5.26 |
| Debt / Equity | — | 0.28 | — |